Partner With Us NRI

Latest Rapid Results

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Q1FY24 Quarterly & FY23 Annual Result Announced for Procter & Gamble Health Ltd.

Pharmaceuticals company Procter & Gamble Health announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Reported a sale of Rs 306.6 crore up by about 3% versus Q4FY22.
    • The sales grew at low single digit against the headwinds of slowing down of the category in Q4FY23.
    • The company reported a PAT of Rs 29.8 crore, a decline of 28% against Q4FY22 on account of higher material costs and one-time employee costs.
  • FY23:
    • The company has recorded a strong performance with sales of Rs 1,206 crore, up by 10% vs. FY22.
    • Profit after tax (PAT) for FY23 is Rs 229 crore, up by 19% versus FY22.
    • The board of directors has recommended a final dividend of Rs 50 per equity share, for FY23.

“We continued our efforts towards brand and category development and thus delivered a strong performance in the fiscal, marked by consistent growth across all our brands. The quarter, however, witnessed a category slowdown across our portfolio. Despite these challenges, we continued our commitment to our strategy of five integrated choices: a portfolio of daily-use products where performance drives brand choice; superiority across product, package, brand communication, retail execution, and value; productivity; constructive disruption of the entire value chain; and a highly efficient and effective organization structure.

We raised awareness and education among our consumers through initiatives like Neuropathy Awareness Week, wherein leading Global Health Experts converged to address the growing Public Health Concern of Peripheral Neuropathy. This also reinforced our efforts towards building an ecosystem for scientific collaboration and knowledge-sharing among healthcare professionals.

We also commemorated World Health Day by launching the Pragati Utsav, an initiative to raise awareness and empower the healthcare professionals of rural hinterlands, on Vitamin B deficiency. We bolstered our go-to-market strategy and strengthened our partnerships across omni-channel stores, increasing the availability and access of our brands across online and offline platforms, thereby helping meet the needs of our consumers and customers.

We launched the first-of-its-kind policies for employees, including the end-to-end support for children with special needs and a co-pay India Day Care policy, We continued to foster an environment of equal opportunities at the workplace. SEHAT, our flagship CSR program, continued to remain a priority during this fiscal year where we continued to strengthen public health through our strategic initiatives,” said Milind Thatte, Managing Director, Procter & Gamble Health.


Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.

Download Our App

Download App
market app